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The diverse pathways and molecules involved in angiogenesis, the formation of new blood vessels, have been
targeted for the treatment of colorectal and other cancers. Vascular endothelial growth factor (VEGF)-A binding to
VEGF receptor (VEGFR)-2 is believed to be the key signaling pathway mediating angiogenesis. Other VEGF pathways
involved in angiogenesis include VEGF-A, VEGF-B, and placental growth factor binding to VEGFR-1, and VEGF-C and
VEGF-D binding to VEGFR-2 and VEGFR-3. VEGF signaling also intersects with other pathways, including
angiopoietin/Tie, Notch, hypoxia-inducible factor, and integrin pathways. The roles of these pathways in tumor
angiogenesis and in various human cancers will be explored in this article. In addition, preclinical and clinical data
on bevacizumab, aflibercept (known as ziv-aflibercept in the US), and investigational antiangiogenic agents in
development for the treatment of colorectal and other cancers will be reviewed.
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Angiogenesis refers to the formation of new blood ves-
sels [1]. As blood vessels are needed to supply nutrients
and oxygen to tissues [2], angiogenesis plays an essential
role in normal growth and development as well as in the
development of cancer [1,3,4]. In normal development,
angiogenesis is needed for embryonic development, bone
formation, and the function of ovaries and other endo-
crine glands [4]. In cancer, angiogenesis is required for
tumor growth and metastasis [1,3].
Angiogenesis is a highly regulated, complex process
orchestrated by a number of intersecting pathways,
including vascular endothelial growth factor (VEGF),
angiopoietins, Notch, and integrins. In normal tissues,
there is a balance between proangiogenic and antiangio-
genic factors [2]. During physiologic angiogenesis in
adults, there is a temporary shift to proangiogenic fac-
tors; this is held in check by inhibitory mechanisms [1,2].
In contrast to normal angiogenesis, tumor angiogenesis
is outside of the control of normal physiologic inhibition,
and there is an imbalance of proangiogenic and antian-
giogenic factors [1,2]. The diversity of pathways and
molecules involved in angiogenesis may offer avenues forCorrespondence: sunw@upmc.edu
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reproduction in any medium, provided the ortherapeutic intervention. This article aims to provide an
overview of tumor angiogenesis, focusing on the role of
VEGF. It will also review preclinical and clinical evidence
for the use of antiangiogenic agents in the treatment of
colorectal and other cancers.Tumor angiogenesis and the role of VEGF
Tumor angiogenesis typically involves the formation of
new blood vessels from pre-existing vessels in a process
known as sprouting angiogenesis [1,5]. Tumors may also
co-opt pre-existing vessels [6]. Compared with the nor-
mal vasculature, the tumor vasculature is abnormal in a
number of different ways. There is loss of the normal
vascular hierarchy of arterioles, capillaries, and venules
[7,8]. The endothelial layer is irregular and contains
spaces that contribute to the leakiness of tumor vessels
[9], proliferating tumor cells cause compression of ves-
sels [10], and interstitial pressure is increased [11]. The
ability of tumor vessels to supply oxygen and remove
waste products is thus compromised, resulting in hyp-
oxia and acidosis in the tumor microenvironment
[12,13]. Abnormalities are also observed in other tumor
vasculature components such as pericytes and the base-
ment membrane. Pericytes have an abnormally weak at-
tachment with endothelial cells and have cytoplasmic
processes that extend away from the vessel wall [8]. Theis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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association with endothelial cells and pericytes, and has
extensions away from the vessel wall [14]. Endothelial cells
in tumor vessels also show altered gene expression [15,16]
and cytogenetic abnormalities such as aneuploidy [17].
The VEGF signaling pathway
The mammalian VEGF signaling pathway includes 5 gly-
coproteins from the VEGF family (VEGF-A, VEGF-B,
VEGF-C, VEGF-D, and placental growth factor [PlGF]), 3
receptors (VEGF receptor [VEGFR]-1 [FLT-1], VEGFR-2
[FLK-1/KDR], and VEGFR-3 [FLT-4]), and 2 co-receptors
(neuropilin [NRP]-1 and NRP-2) (Figure 1) [5,18-26]. In
addition, there are multiple isoforms of VEGF-A (VEGF121,
VEGF165, VEGF189, and VEGF206) [5]. The receptors for
the various VEGF ligands are tyrosine kinases and are
found primarily on vascular endothelial cells [18,26].
VEGF-A binding to VEGFR-2 is believed to be the key
signaling pathway mediating angiogenesis [18,27]. VEGF-
A enhances endothelial cell proliferation and survival,
promotes endothelial cell migration, increases vascular
permeability, and alters gene expression [5,18]. Levels of
VEGF-A have been shown to be increased in many can-
cers, including colorectal, prostate, and breast [28]. Down-
stream signaling activated by VEGF-A binding to VEGFR-2
includes the PLC-gamma/PKC/Ras/Raf/MEK/MAPK sig-
naling pathway [29,30]. Other VEGF family members,
along with other signaling mediators, affect and overlap
with the function of VEGF-A [26,31,32]. For instance,
PlGF, fibroblast growth factor (FGF), and platelet-derived
growth factor (PDGF) can modulate the effects of VEGF-A
on angiogenesis, and VEGF-A can form heterodimers withNP1/2 VEGFR1 
VEGF Family 
NP1/2 
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VEGF Receptors 
VEGF-A
PlGF 
VEGF-B 
Figure 1 The VEGF family. Positive and negative modulation of angiogenPlGF or VEGF-B [26]. Because of alternative splice var-
iants, an enormous diversity of heterodimerization with
different functional properties may be formed, which pre-
sents a challenge to assessing the functional consequences.
In addition, VEGF-A has overlapping function with VEGF-C
and VEGF-D [26]. VEGF-A-mediated signaling also inter-
sects with angiopoietin (Ang)/Tie, Notch/delta-like ligand
(Dll)4, hypoxia-inducible factor (HIF)-1α and HIF-2α, and
integrin pathways [26,31,32] (Figure 2).
Like VEGFR-2, VEGFR-1 is expressed on vascular
endothelial cells, but it is also expressed on other cell
types, including monocytes and macrophages [26,36].
The affinity of VEGFR-1 for VEGF-A is greater than that
of VEGFR-2, although it has weak kinase activity, and it
is thought to be a negative regulator of angiogenesis
[37]. In cancer, VEGFR-1 appears to play a role in the
epithelial-to-mesenchymal transition [38,39]. VEGF-B
binding to VEGFR-1 was shown to be associated with
increased microvascular density in oral squamous cell
carcinoma [40], but it was not associated with tumor vas-
cularity in breast cancer [41] and it inhibited tumor
growth in a mouse pancreatic neuroendocrine tumor
model [42]. In a non-tumor model of pathological angio-
genesis, VEGF-B promoted survival of endothelial cells,
pericytes, and smooth muscle cells and upregulated the
expression of prosurvival genes [43]. VEGF-B shows
increased expression in multiple cancers, including ovar-
ian, colorectal, renal cell, and prostate; its expression is
associated with disease stage and expression of its recep-
tor, VEGFR-1, predicts poor prognosis [36].
PlGF, another ligand for VEGFR-1, is thought to play a
role in the angiogenic switch in pathological conditionsVEGFR2 VEGFR3 NP1/2 
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Figure 2 Selected crosstalk between VEGF and other signaling pathways. VEGF signaling intersects with a number of other signaling
pathways, including Ang/Tie, Notch/Dll4, integrins, and hypoxia to orchestrate tumor angiogenesis [26,27,31-35]. Ang = angiopoietin;
Dll4 = delta-like ligand 4; HIF = hypoxia-inducible factor; PlGF = placenta growth factor; VEGF = vascular endothelial growth factor;
VEGFR = vascular endothelial growth factor receptor. Dashed arrow indicates Ang-2 can serve as a partial Tie-2 agonist under certain conditions.
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pression [45] and has a synergistic effect on VEGF-A
signaling in cancer and other pathological forms of
angiogenesis [44]. PlGF appears to promote the growth
of tumor cells in an autocrine/paracrine manner [46].
PlGF has been shown to be upregulated in and prognos-
tic for cancers, including gastric, colorectal, lung, breast,
renal cell, hepatocellular, and brain [36].
VEGF-C and VEGF-D bind to the receptors VEGFR-2
and VEGFR-3 [26]. VEGF-C expression is associated with
advanced metastatic disease for colorectal cancer [47] and
it plays a role in lymphangiogenesis and/or metastasis to
lymph nodes in multiple cancers, including colorectal [48]
and breast [49-51]. VEGF-D is also involved in lymphan-
giogenesis and lymphatic metastasis [52,53].
Crosstalk between the VEGF signaling pathway and other
angiogenic signaling pathways
The angiopoietins Ang-1, Ang-2, and Ang-4 bind to the
receptor tyrosine kinases Tie1 and Tie2 on vascular endo-
thelial cells and are involved in the angiogenic switch, me-
tastasis, and lymphangiogenesis [6,31]. Ang-1 is expressed
by mural cells, fibroblasts, and non-vascular normal andtumor cells, whereas Ang-2 is expressed primarily by
endothelial cells and behaves in an autocrine manner [31].
Overexpression of Ang-2 has been shown to be associated
with poor prognosis for a number of different cancers
[31]. The Ang/Tie signaling pathway interacts with VEGF-
A-mediated signaling in tumor angiogenesis [6,31]. Ang-2
is upregulated by proangiogenic factors, including VEGF-A,
PDGFB, and insulin-like growth factor (IGF)1 [31]
(Figure 2). Ang-2 causes pericytes to dissociate from endo-
thelial cells in pre-existing vessels and, in the presence of
VEGF-A, this leads to angiogenesis [6,31]. Ang-1 expressed
by pericytes appears to help to maintain the integrity of
blood vessels [31].
The Notch receptors Notch 1 and Notch 4 and the
ligands jagged 1, Dll1, and Dll4 are expressed by vascular
endothelial cells [27] and are involved in sprouting angio-
genesis [31]. There are multiple modes of crosstalk between
Notch/Dll4 and VEGF signaling (Figure 2). Dll4 expression
and Notch signaling are induced by VEGF-A and VEGF-C
[27,33]. VEGFR-3 regulates Notch signaling and the con-
version of tip cells to stalk cells in sprouting angiogenesis
[34]. Notch upregulates VEGFR-3 and allows VEGF-A/
VEGFR-2-independent angiogenesis [35]. In addition, Dll4/
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apy through multiple different mechanisms, e.g. decreased
levels of hypoxia-induced VEGF and increased levels of the
VEGF receptor VEGFR1 in the tumor stroma, decreased
levels of VEGFR2 in large blood vessels, and reduced levels
of VEGFR3 overall [54].
Integrins and hypoxia may also have an impact on
VEGF and other signaling components in tumor angio-
genesis (Figure 2). αv integrins, which are expressed on
multiple cell types, contribute to angiogenesis [32]. These
and other integrins interact with the VEGF/VEGFR and
Ang/Tie signaling pathways [32]. Hypoxia, through HIF-
1α and HIF-2α, leads to increased expression of VEGF-A;
hypoxia may also regulate PlGF expression, which may be
more complicated. Basically, tissue hypoxia may not only
elevate the abundance of VEGF-A, but may also increase
other angiogenic regulatory factors, therefore leading to
angiogenic activity alteration [26].
VEGF-A, often referred to as VEGF without a suffix [4],
is the sole target of bevacizumab, a humanized monoclonal
antibody approved for the treatment of colorectal and
other cancers [55] and aflibercept (VEGF Trap, known in
the US as ziv-aflibercept), is a recombinant fusion protein
with receptor components of VEGFR-1 and VEGFR-2 that
binds multiple ligands in the angiogenesis network (VEGF-A,
VEGF-B, and PlGF) [56]. Aflibercept was recently approved
for use by the US FDA with the US name of ziv-aflibercept,
in combination with 5-fluorouracil, leucovorin, irinotecan
(FOLFIRI) for patients with metastatic colorectal cancer
(mCRC) that is resistant to or has progressed following an
oxaliplatin-containing regimen. In addition to agents that
target the various VEGFs and VEGFRs, agents that target
other angiogenic mediators, including Ang-1 and −2,
Notch signaling, HIF-1α, and integrins, and that are in clin-
ical development are listed in the NCT registry (forTable 1 Recent and ongoing phase 3 trials of antiangiogenic
Trial
Biologics
Bevacizumab in combination with crossover fluoropyrimidine-based chemoth
(stratum 1: AIO-IRI, FOLFIRI, CAPIRI or XELIRI; stratum 2: FUFOX, FOLFOX, CAP
Aflibercept plus irinotecan and 5-FU following failure of an oxaliplatin-based
Ramucirumab plus FOLFIRI following progression with first-line bevacizumab
and fluoropyrimidine
TKIs
Brivanib alaninate in combination with the EGFR monoclonal antibody cetux
Cediranib plus chemotherapy (FOLFOX or XELOX) as first-line treatment (HOR
Cediranib plus FOLFOX vs bevacizumab plus FOLFOX as first-line treatment (
Regorafenib plus best supportive care following failure of standard therapies
Sunitinib plus FOLFIRI as first-line treatment
Vatalanib plus oxaliplatin/5-FU/leucovorin following previous treatment with
*Note that there are additional phase 3 studies of bevacizumab for the treatment o
TKIs = tyrosine kinase inhibitors.example NCT01210222, NCT01193868, NCT011202-
88, and NCT00915278).
Benefits of antiangiogenic agents in the treatment of
metastatic colorectal cancer: preclinical and clinical
evidence
As mentioned above, bevacizumab and aflibercept are anti-
angiogenic agents approved for the treatment of mCRC
[55,56]. Other antiangiogenic therapies currently in late-
stage clinical trials for mCRC include the anti-VEGFR-2
monoclonal antibody ramucirumab, and the tyrosine kin-
ase inhibitor (TKI) regorafenib; additional TKIs (brivanib
alaninate, cediranib, sunitinib, and vatalanib) had negative
results in phase 3 trials (Table 1). Preclinical studies with
these agents supported their further development for the
treatment of colorectal cancer and other malignancies.
Preclinical data
In preclinical models, bevacizumab demonstrated antitu-
mor activity both as a single agent and in combination
with chemotherapy or radiotherapy [57]. In tumor xeno-
graft models, bevacizumab was shown to decrease tumor
weight and size, tumor growth, vascular permeability, as-
cites formation, and the diameter and density of tumor
vessels [57]. One of the proposed mechanisms by which
bevacizumab is believed to enhance cytotoxic treatments
is via “normalization” of the tumor vasculature [57], and
the use of bevacizumab in combination with chemother-
apy or radiotherapy has been shown to have at least
additive activity in certain tumor models [57].
Aflibercept (VEGF Trap) is a recombinant fusion pro-
tein that contains domains from VEGFR-1 and VEGFR-2
and targets VEGF-A as well as VEGF-B and PlGF [58,59].
In certain tumor xenograft models, aflibercept inhibited
the growth of new and established tumors and tumoragents for the treatment of mCRC
ClinicalTrials.gov identifier
erapy beyond progression
OX or XELOX) (ML 18147 study)*
NCT00700102
regimen (VELOUR) NCT00561470
, oxaliplatin, NCT01183780
imab following previous chemotherapy NCT00640471
IZON II) NCT00399035
HORIZON III) NCT00384176
(CORRECT) NCT01103323
NCT00457691
irinotecan NCT00056446
f mCRC.
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flow; and inhibited metastases and ascites formation [60].
Aflibercept also increased tumor hypoxia and decreased
expression of tumor vascular genes and decreased activa-
tion of vascular endothelial signaling pathways [60]. In
tumor xenografts, aflibercept in combination with other
agents (radiotherapy, chemotherapy, or trastuzumab)
showed greater inhibition of tumor growth and tumor
vasculature than was observed with the individual agents
alone [60].
In a recent study, the binding characteristics of bevaci-
zumab and aflibercept were compared using several pre-
clinical assessments [61]. Aflibercept showed tight binding
to VEGF 165; dissociation constant (KD) was significantly
lower with aflibercept compared with dimerized VEGFR1
or VEGFR2. Additionally, the KD of aflibercept (0.490 pM)
was approximately 100-fold lower compared with that of
bevacizumab (58 pM), suggesting a 100-fold tighter bind-
ing to VEGF 165 [61].
Differences in biologic activity were also demonstrated
preclinically. In a study of VEGF-A–induced activation
of VEGFR1, aflibercept demonstrated 92-fold greater
potency than bevacizumab in an assay in which VEGFR1
activation was induced by VEGF-A 165 or VEGF-A 121
[61]. Aflibercept also inhibited VEGFR1 activation by PlGF2,
[61]. Aflibercept also inhibited activation of VEGFR2 acti-
vation induced by VEGF-A 165 or VEGF-A 121, which
may suggest some clinical benefits since binding kinetics
and affinity are important determinants of the biological
activity of antibody-like drugs [61].
Ramucirumab, a fully human monoclonal antibody
against VEGFR-2, was designed to bind to a VEGFR-2
epitope involved in ligand binding [62]. It has shown
anticancer activity alone and in combination with other
agents in preclinical models of leukemia, solid tumors,
and metastases [63-65].
Various antiangiogenic TKIs have also demonstrated pre-
clinical activity in cancer models. Cediranib, a VEGFR-2
TKI, inhibited tumor growth and reduced microvessel
density in tumor xenograft models [66]. Regorafenib, a
multikinase inhibitor whose targets include VEGFR-1-3
and Tie2, induced tumor growth inhibition or shrinkage
and reduced extravasation in tumor xenograft models
[67,68]. Brivanib, a dual VEGFR-2/FGFR-1 kinase inhibi-
tor, reduced tumor proliferation, vascular density, and
microcirculation; inhibited VEGF- and FGF-driven angio-
genesis; and induced apoptosis in tumor xenograft models
[69,70]. Sunitinib, a multikinase inhibitor that targets
VEGFR-2, PDGFR, KIT, and FLT3, inhibited VEGFR-2
phosphorylation and VEGF-induced vascular permeability
and caused tumor regression, growth arrest, or growth in-
hibition in tumor xenografts [71]. Vatalanib, an inhibitor
of VEGFRs and other kinases, decreased tumor growth,
metastasis, microvascular density, and blood flow intumor xenograft models and induced tumor cell apoptosis
[72-74].
Based on these preclinical data demonstrating antican-
cer activity, these agents moved forward into clinical
studies for mCRC and other cancers.
Clinical data
Bevacizumab The clinical benefit of antiantiogenesis
agents in treatment of mCRC has been established. Based
on encouraging data of a 3-arm phase 2 study [75], several
pivotal phase 3 trials demonstrated that bevacizumab
improved overall survival as first- or second-line therapy in
combination with fluoropyrimidine-containing regimens
(either combined with oxaliplatin or irinotecan) in patients
with mCRC [76,77]. In the initial phase 3 pivotal trial, me-
dian overall survival (mOS) was increased from 15.6
months in patients who received IFL (bolus 5-FU, leucov-
orin, and irinotecan), but only to 20.3 months in patients
who received IFL + bevacizumab (P<0.001) as first line
therapy in mCRC [76]. The E3200 study showed the bene-
fit of bevacizumab as second line therapy when combined
with FOLFOX (infusional 5-FU and oxaliplatin) with mOS
of 10.8 vs. 12.9 months (P=0.0018) [77]. Together, these
trials confirmed a survival benefit with bevacizumab in
both the first- and second-line settings for mCRC.
Bevacizumab-associated toxicities identified in early trials
of bevacizumab included hemorrhage, thromboembolism,
proteinuria, and hypertension [76]. In phase 3 trials of bev-
acizumab plus chemotherapy in patients with mCRC, the
incidence of grade ≥3 bleeding/hemorrhage was 2% to
3.4% with bevacizumab versus <1% to 2.5% with compara-
tor; the incidence of grade ≥3 thromboembolism (reported
in 2 trials) was 3.4% to 10% with bevacizumab versus 2.5%
to 6% with comparator; the incidence of grade ≥3 venous
thromboembolic events (VTEs, reported in 1 trial) was 8%
with bevacizumab versus 5% with comparator; the inci-
dence of grade ≥3 proteinuria was <1% in either arm; and
the incidence of grade ≥3 hypertension was 4% to 11% with
bevacizumab versus 1% to 2.3% with comparator [76-78].
Gastrointestinal perforation was also reported in phase 3
trials of bevacizumab in patients with mCRC: <1% to 1.5%
with bevacizumab versus 0% to <1% with comparator
[76-78].
Since antiangiogenic agents are not traditional cytotoxic
chemotherapy agents, the question remains whether their
antitumor efficacy may be maintained after patients’ disease
has progressed after a bevacizumab-containing chemother-
apy regimen. A registry study which suggested a significant
survival benefit was controversial because of the registry
study design [79]. There were no randomized study data
until recently. In the TML (ML 18147) study, all patients
were previously treated with bevacizumab in combination
with either FOLFOX or FOLFIRI. After disease progression,
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were not exposed to (either FOLFIRI or FOLFOX) with
continuous bevacizumab. The overall survival was signifi-
cantly improved with continuous bevacizumab plus che-
motherapy versus chemotherapy alone as second line in
mCRC patients who had progressed on first-line beva-
cizumab-containing regimens (11.2 versus 9.8 months,
P=0.0211) [80]. This study validates the importance of con-
tinued antiangiogenic therapy in mCRC patients following
progression.
Regorafenib Another randomized phase 3 study
(CORRECT trial) with a total 760 patients who were
treated with standard therapies including bevacizumab-
containing regimens demonstrated the efficacy of regorafe-
nib in both overall survival (6.4 versus 5.0 months,
HR=0.773, P=0.0051) and progression-free survival (1.9
versus 1.7 months, HR=0.493, P<0.000001) compared with
placebo; the most common grade ≥3 adverse events were
hand-foot reaction (17%), fatigue (15%), diarrhea (8%),
hyperbilirubinemia (8%), and hypertension (7%) [81]. This
study was the first to demonstrate the efficacy of an oral
TKI in prolonging survival in patients with mCRC.
Aflibercept Data from a phase 3 trial (VELOUR)
(N=1226, with 28.3% of patients having had previous
bevacizumab exposure) demonstrated that aflibercept plus
FOLFIRI in patients with mCRC who had progressed
following an oxaliplatin containing regimen significantly
improved overall survival (13.5 months versus 12.06
months, HR=0.817, P=0.0032) and progression-free survival
(6.90 months versus 4.67 months, HR=0.758, P=0.00007)
compared with placebo plus FOLFIRI in mCRC patients
previously treated with FOLFOX [82,83]. These data led to
the FDA approval of aflibercept (ziv-aflibercept) for the
treatment of mCRC following oxaliplatin-based chemother-
apy. While the progression-free survival benefit remained
in the prior bevacizumab-treated patients (6.7 versus 3.9
months, HR=0.661 [95% CI 0.512-0.852]) based on the pre-
specified subgroup analysis, the study was not powered to
show a treatment difference between arms; therefore, no
definitive conclusions may be drawn concerning the benefit
of aflibercept in the prior bevacizumab-treated subgroup.
The most common grade 3–4 adverse events with more
than 2% higher incidence with aflibercept were diarrhea,
asthenia/fatigue, stomatitis/ulceration, infections, hyper-
tension, gastrointestinal/abdominal pains, neutropenia/
neutropenic complications, and proteinuria.
Cediranib In the HORIZON II trial, cediranib plus chemo-
therapy (FOLFOX or XELOX) significantly improved
progression-free survival (HR=0.84) but not overall survival
(HR=0.94) compared with chemotherapy plus placebo;treating to progression with cediranib plus chemotherapy
appeared to have a beneficial effect [84].
Brivanib In the NCIC Clinical Trials Group and AGITG
CO.20 trial, brivanib alaninate plus cetuximab signifi-
cantly improved progression-free survival (5.0 versus 3.4
months, HR=0.72, P<0.0001) but not overall survival
(8.8 versus 8.1 months, HR=0.88, P=0.12) compared
with cetuximab plus placebo; the most frequent grade
≥3 adverse events with brivanib alaninate were fatigue
(25%), hypertension (11%), and rash (5%) [85].
Conclusions
The importance of angiogenesis in cancer, and an increased
understanding of the network of signaling pathways that
mediate it, have led to the development of a number of anti-
angiogenic agents for the treatment of cancer. Bevacizumab
is approved for the first- or second-line treatment of mCRC
when added to intravenous 5-fluorouracil-based regimens,
and aflibercept was approved by the FDA when added to
FOLFIRI in patients with mCRC previously treated with an
oxaliplatin-based regimen. Other antiangiogenic agents are
in late-stage clinical development. The addition of bevaci-
zumab or aflibercept to chemotherapy in patients with
mCRC has demonstrated improved overall survival com-
pared with chemotherapy alone, and regorafenib added to
best supportive care has demonstrated improved survival
compared with placebo. Insight into how angiogenic sig-
naling pathways intersect may aid in the design of agents
with improved efficacy and safety profiles and a reduced
risk of resistance. Additional research is needed regarding
how to sequence and combine approved and investiga-
tional antiangiogenic agents for the treatment of colorectal
and other cancers.
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